DoD Awards $2.2B Contract for Molnupiravir Antiviral to Merck Sharp & Dohme LLC
Contract Overview
Contract Amount: $2,205,000,834 ($2.2B)
Contractor: Merck Sharp & Dohme LLC
Awarding Agency: Department of Defense
Start Date: 2021-06-07
End Date: 2023-07-13
Contract Duration: 766 days
Daily Burn Rate: $2.9M/day
Competition Type: FULL AND OPEN COMPETITION
Number of Offers Received: 1
Pricing Type: FIRM FIXED PRICE
Sector: Healthcare
Official Description: COVID-19 ORAL ANTIVIRAL MK-4482 (MOLNUPIRAVIR)
Place of Performance
Location: KENILWORTH, UNION County, NEW JERSEY, 07033
Plain-Language Summary
Department of Defense obligated $2.21 billion to MERCK SHARP & DOHME LLC for work described as: COVID-19 ORAL ANTIVIRAL MK-4482 (MOLNUPIRAVIR) Key points: 1. Significant investment in a critical pharmaceutical product. 2. Sole awardee suggests potential for limited competition or unique offering. 3. Contract duration of over two years indicates sustained demand. 4. Firm fixed price contract provides cost certainty for the government.
Value Assessment
Rating: good
The contract value of $2.2 billion is substantial for a pharmaceutical product. Benchmarking against similar large-scale drug procurement contracts would be necessary for a precise value assessment, but the firm fixed price suggests a negotiated agreement aiming for cost efficiency.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
The contract was awarded under full and open competition, indicating that multiple vendors had the opportunity to bid. This method generally promotes competitive pricing and allows the government to select the best value offer.
Taxpayer Impact: The firm fixed price structure aims to protect taxpayers by locking in costs, assuming the negotiated price was competitive at the time of award.
Public Impact
Ensures availability of a key antiviral medication for public health needs. Supports the pharmaceutical manufacturing sector and associated supply chains. Potential for broader public health impact beyond immediate government use.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Potential for price increases if market conditions change significantly.
- Dependence on a single supplier for a critical medication.
Positive Signals
- Secures a vital medical countermeasure.
- Firm fixed price provides budget predictability.
- Awarded through full and open competition.
Sector Analysis
The pharmaceutical preparation manufacturing sector is characterized by high R&D costs, stringent regulatory requirements, and significant market demand, especially for critical medicines like antivirals. Government contracts in this sector often involve large sums due to the nature of drug development and procurement.
Small Business Impact
This contract was awarded to a large, established pharmaceutical company, Merck Sharp & Dohme LLC. There is no indication of small business participation in this specific award, which is common for large-scale, specialized procurements in the pharmaceutical industry.
Oversight & Accountability
The definitive contract structure with a firm fixed price suggests clear terms and conditions. Oversight would focus on delivery schedules, quality control, and adherence to the contract's pricing structure to ensure accountability and value for taxpayer funds.
Related Government Programs
- Pharmaceutical Preparation Manufacturing
- Department of Defense Contracting
- Department of the Army Programs
Risk Flags
- Sole source award for a critical item.
- Long contract duration.
- Potential for price escalation in future contracts.
- Dependence on a single manufacturer.
Tags
pharmaceutical-preparation-manufacturing, department-of-defense, nj, definitive-contract, billion-dollar
Frequently Asked Questions
What is this federal contract paying for?
Department of Defense awarded $2.21 billion to MERCK SHARP & DOHME LLC. COVID-19 ORAL ANTIVIRAL MK-4482 (MOLNUPIRAVIR)
Who is the contractor on this award?
The obligated recipient is MERCK SHARP & DOHME LLC.
Which agency awarded this contract?
Awarding agency: Department of Defense (Department of the Army).
What is the total obligated amount?
The obligated amount is $2.21 billion.
What is the period of performance?
Start: 2021-06-07. End: 2023-07-13.
What was the basis for the negotiated firm fixed price, and how does it compare to market prices for similar antivirals at the time of award?
The basis for the firm fixed price would typically involve detailed cost proposals from bidders, market analysis, and negotiation between the Department of Defense and Merck. Comparing it to market prices for similar antivirals requires access to proprietary pricing data and market intelligence reports from the period of award. Without this specific data, a definitive assessment of the price's competitiveness is challenging, though the full and open competition process suggests an effort to achieve a favorable price.
What are the potential risks associated with relying on a single supplier for a critical antiviral medication, particularly concerning supply chain disruptions or future price negotiations?
Relying on a single supplier, even with a firm fixed price contract, carries risks. Supply chain disruptions, whether due to manufacturing issues, raw material shortages, or geopolitical events, could impact availability. Furthermore, while the current contract has a fixed price, future procurements or contract extensions could be subject to price increases if market conditions or the supplier's costs change significantly. This highlights the importance of ongoing market surveillance and contingency planning.
How effective has Molnupiravir proven to be in clinical settings, and does this contract align with public health recommendations for its use?
Molnupiravir's effectiveness has been a subject of ongoing clinical evaluation. While it received Emergency Use Authorization and later FDA approval, its efficacy and role compared to other antivirals like Paxlovid have been debated, with some studies suggesting lower effectiveness or higher risk profiles. The contract's alignment with public health recommendations would depend on the specific guidance from agencies like the CDC and FDA at the time of procurement and throughout the contract's duration, considering evolving clinical data.
Industry Classification
NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing
Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE
Solicitation ID: W911QY20SC001
Offers Received: 1
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Parent Company: Merck & CO., Inc.
Address: 2000 GALLOPING HILL RD, KENILWORTH, NJ, 07033
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business
Financial Breakdown
Contract Ceiling: $3,700,200,834
Exercised Options: $2,205,000,834
Current Obligation: $2,205,000,834
Contract Characteristics
Commercial Item: COMMERCIAL PRODUCTS/SERVICES
Cost or Pricing Data: NO
Timeline
Start Date: 2021-06-07
Current End Date: 2023-07-13
Potential End Date: 2023-07-13 00:00:00
Last Modified: 2023-07-14
More Contracts from Merck Sharp & Dohme LLC
- Vsccine for Children (VFC) 2014 — $1.5B (Department of Health and Human Services)
- 2017 Vaccines for Children — $1.5B (Department of Health and Human Services)
- Vaccine for Children 2013 — $1.4B (Department of Health and Human Services)
- Federal Contract — $236.3M (Department of Health and Human Services)
- Ervebo Procurement — $155.8M (Department of Health and Human Services)
Other Department of Defense Contracts
- Federal Contract — $51.3B (Humana Government Business Inc)
- Lrip LOT 12 Advance Acquisition Contract — $35.1B (Lockheed Martin Corporation)
- SSN 802 and 803 Long Lead Time Material — $34.7B (Electric Boat Corporation)
- 200204!008532!1700!AF600 !naval AIR Systems Command !N0001902C3002 !A!N! !N! !20011026!20120430!008016958!008016958!834951691!n!lockheed Martin Corporation !lockheed Blvd !fort Worth !tx!76108!27000!439!48!fort Worth !tarrant !texas !+000026000000!n!n!018981928201!ac15!rdte/Aircraft-Eng/Manuf Develop !a1a!airframes and Spares !2ama!jast/Jsf !336411!E! !3! ! ! ! ! !99990909!B! ! !A! !a!n!r!2!002!n!1a!a!n!z! ! !N!C!N! ! ! !a!a!a!a!000!a!c!n! ! ! !Y! !N00019!0001! — $34.2B (Lockheed Martin Corporation)
- KC-X Modernization Program — $32.0B (THE Boeing Company)